ICLRICON Public Limited Company
Price
-5.6%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, price roughly fair, growth fading, the market undecided.
ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. We offer a full range of clinical, consulting and commercial services that range from clinical development strategy, planning and trial design, to full study execution, and post-market commercialization. ICON provides its services across a range of clinical outsourcing operating models including strategic partnerships, preferred provider, full-service delivery to functional service provision and stand-alone services.
In the company’s own words · 20-F filed May 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
ICON Public Limited Company (ICLR) reported revenue of $2.06B in Q2 2026 (quarter ended Jun 30, 2026), up 1.2% from the same quarter a year earlier. That came with a gross margin of 23% and net income of $73M (3.5% of revenue). For the full year FY2025, revenue was $8.25B (+0.8% year on year) and net income $229M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #3 of 21 by RyuScore